Author

T. Lechmere

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Organism:mouse· 1

Frequent Co-Authors

K. J. Doores· 3 shared A. Kurshan· 2 shared A. Waters· 2 shared C. Graham· 2 shared C. Mant· 2 shared J. Fox· 2 shared J. Seow· 2 shared M. H. Malim· 2 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

K. J. Doores

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Broad and potent neutralizing mAbs are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection

J. Seow, Z. A. Shalim, C. Graham, S. Kimuda, A. Pillai, T. Lechmere, A. Kurshan, A. Khimji, L. Snell, G. Nebbia, C. Mant, A. Waters, J. Fox, M. H. Malim, K. J. Doores

The paper shows that vaccinated individuals develop broad neutralizing mAbs after Delta/BA.1 infection, but these mAbs are less effective against newer variants.

bioRxiv · Mar 30, 2023 · PreprintImmunology

Omicron breakthrough infections in vaccinated or previously infected hamsters

J. Zhou, K. Sukhova, P. F. McKay, A. Kurshan, Y. Yau, T. Lechmere, J. C. Brown, M. Moshe, R. Kugathasan, L. B. Snell, J. D. Edgeworth, R. J. Shattock, K. J. Doores, T. P. Peacock, W. S. Barclay

This study shows Delta and Omicron SARS-CoV-2 variants do not provide cross-protective immunity against reinfection in hamsters.

bioRxiv · May 20, 2022Microbiology

ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants

J. Seow, C. Graham, S. R. Hallett, T. Lechmere, T. J. A. Maguire, I. Huettner, D. Cox, R. Roberts, A. Waters, C. C. Ward, C. Mant, M. J. Pitcher, J. Spencer, J. Fox, M. H. Malim, K. J. Doores

This study isolates monoclonal antibodies from a vaccinated individual and shows they neutralize multiple SARS-CoV-2 variants effectively.

bioRxiv · Sep 27, 2021Immunology